{"schema_version":"secwatch.filing_event.v1","accession":"0001636282-26-000113","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-09-08T12:01:57+00:00","discovered_at":"2026-09-08T12:05:01.444391+00:00","generated_at":"2026-09-08T12:05:07.874912+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Spyre SPY003 Phase 2 UC: 10-point RHI reduction (p<0.0001), 20% remission, 30% endoscopic improvement","bullets":["SPY003 met primary endpoint: 10.0-point reduction in RHI from baseline at Week 12 (p<0.0001) in 44 patients with moderate-to-severe UC.","Secondary endpoints: 20% clinical remission by modified Mayo Score, 30% endoscopic improvement, -3.5 change in mMS.","Safety: 19 TEAEs (43%), 3 SAEs deemed not drug-related, no drug-related SAEs or deaths; consistent with IL-23 class.","Completes proof-of-concept for all three IBD components (SPY001, SPY002, SPY003); Part B combination trial enrolling, topline data expected 2027.","Additional readouts: SKYWAY (SPY072) 4Q 2026; SKYLIGHT (HS) late 2027/early 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-26-000113","json":"https://secwatch.observer/filing/0001636282-26-000113.json","markdown":"https://secwatch.observer/filing/0001636282-26-000113.md","text":"https://secwatch.observer/filing/0001636282-26-000113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000113/0001636282-26-000113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000113/syre-20260908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T12:05:07.874912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}